Latest Breaking News On - Urologic oncology - Page 2 : comparemela.com

ASCO 2024: Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial

advanced adrenocortical carcinoma, camrelizumab, Apatinib, Camrelizumab plus Apatinib.

United statesZhigong weiSociety of urologic oncologyAmerican society of clinical oncologyUniversity of torontoSichuan universityDepartment of biotherapyCancer centerClinical oncologyAnnual meetingWest china hospitalRashid sayyidUrologic oncologyClinical fellowAdvanced adrenocortical

ASCO 2024:A Multi-Institution Analysis of Outcomes With First-Line Systemic Therapy for 102 Patients With Metastatic Chromophobe Renal Cell Carcinoma

metastatic chromophobe RCC patients receiving 1st line systemic therapy, first-line systemic therapy for metastatic chromophobe renal cell carcinoma (RCC).

United statesNew yorkJohns hopkinsSahil doshiUniversity of torontoAmerican society of clinical oncologySociety of urologic oncologyClinical oncologyAnnual meetingHematology fellowMemorial sloan kettering cancer centerRashid sayyidUrologic oncologyClinical fellow

ASCO 2024: Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?

ASCO 2024 diagnostic and therapeutic strategies in renal cell carcinoma (RCC), vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).

San diegoUnited statesUnited kingdomBelzutifan weliregYu wei chenLaurence albigesDepartment of medicineSociety of urologic oncologyUniversity of californiaAmerican society of clinical oncologyUniversity of torontoSan diego medical centerNational cancer databaseClinical oncologyAnnual meetingHypoxia inducible factor

ASCO 2024: Avelumab as Neoadjuvant Therapy in Patients with Muscle-Invasive Urothelial Carcinoma: Survival Data of AURA Trial, Oncodistinct 004

ASCO 2024, Muscle-Invasive Urothelial Carcinoma, Muscle invasive bladder cancer (MIBC), Avelumab, Avelumab as Neoadjuvant Therapy, AURA Trial, Oncodistinct 004.

Bruxelles capitaleUnited statesInstitut jules bordetJeremy blancUniversity of torontoSociety of urologic oncologyAmerican society of clinical oncologyClinical oncologyAnnual meetingUniversitaire de bruxellesLibre de bruxellesRashid sayyidUrologic oncologyClinical fellowNeoadjuvant therapy before radical cystectomy

Fox Chase s Dr Daniel Geynisman Named Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network

Fox Chase s Dr Daniel Geynisman Named Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Danielm geynismanUniversity of pittsburgh school medicineUniversity of pittsburgh medical centerJournal of the national comprehensive cancer networkOncology research programNational comprehensive cancer networkFox chase cancer centerDivision of genitourinary medical oncologyUniversity of chicago medical centerMaclean centerGenitourinary medical oncologyAssociate professorNational comprehensive cancerChase cancer centerPractice guidelinesChief executive officer